Safe Threshold to Discontinue Phototherapy in Hemolytic Disease of Newborn
Recruiting
N/A
Interventional Study
Hemolytic Disease of Newborn
Neonatal Hyperbilirubinemia
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
At a Glance
- Age
- 1 Hour – 14 Days
- Sex
- Any
- Study type
- Interventional
- Purpose
- Prevention
- Participants needed
- 84 (estimated)
- Sponsor
- Ministry of Health, Saudi Arabia · Government
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
We hypothesized that adopting a lower rather than a higher threshold for phototherapy discontinuation will be associated with reduced rates of rebound hyperbilirubinemia in term and late preterm neonates with hemolytic disease of newborn.
Objectives: The investigators aimed to compare the safety of implementing low-threshold, compared to high- threshold, of TSB for phototherapy interruption in te…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
Healthy term and late-preterm neonates more than or equal 35 weeks gestation with hemolytic disease of newborn will be included. Enrolled infants should have evidence of hemolysis as defined by any of the following criteria:
1. positive DAT and blood group iso-immunization (ABO…
Contacts